Evidence map›Paper›PMID 36639629›Full record

ArticleBMC cancer2023

Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytes.

Senyao Shao, Lars Uwe Scholtz, Sarah Gendreizig, Laura Martínez-Ruiz, Javier Florido, Germaine Escames, Matthias Schürmann, Carsten Hain, Leonie Hose, Almut Mentz and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Senyao Shao *Department of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Lars Uwe Scholtz *Department of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Sarah GendreizigDepartment of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Laura Martínez-RuizBiomedical Research Center, Health Sciences Technology Park, University of Granada, 18016, Granada, Spain.
Javier FloridoBiomedical Research Center, Health Sciences Technology Park, University of Granada, 18016, Granada, Spain.
Germaine EscamesBiomedical Research Center, Health Sciences Technology Park, University of Granada, 18016, Granada, Spain.
Matthias SchürmannDepartment of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Carsten HainCenter for Biotechnology (CeBiTec), Universität Bielefeld, Bielefeld, Germany.
Leonie HoseDepartment of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Almut MentzDepartment of Pathology, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Pascal SchmidtCenter for Biotechnology (CeBiTec), Universität Bielefeld, Bielefeld, Germany.
Menghang WangDepartment of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Peter GoonDepartment of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Michael WehmeierDepartment of Laboratory Medicine, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Frank BraschDepartment of Pathology, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Jörn KalinowskiCenter for Biotechnology (CeBiTec), Universität Bielefeld, Bielefeld, Germany.
Felix Oppel *Department of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany. felix.oppel@klinikumbielefeld.de.
Holger Sudhoff *Department of Otolaryngology, Head and Neck Surgery, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany. holger.sudhoff@klinikumbielefeld.de.
Bielefeld University · DEKlinikum Bielefeld · DEInstituto de Investigación Biosanitaria de Granada · ESPeking University · CNUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew concepts for a more effective anti-cancer therapy are urgently needed. Experimental flaws represent a major counter player of this development and lead to inaccurate and unreproducible data as well as unsuccessful translation of research approaches into clinics. In a previous study we have created epithelial cell cultures from head and neck squamous cell carcinoma (HNSCC) tissue.

methodsWe characterize primary cell populations isolated from human papillomavirus positive HNSCC tissue for their marker expression by RT-qPCR, flow cytometry, and immunofluorescence staining. Their sensitivity to MDM2-inhibition was measured using cell viability assays.

resultsPrimary HNSCC cell cultures showed the delayed formation of spheroids at higher passages. These spheroids mimicked the morphology and growth characteristics of other established HNSCC spheroid models. However, expression of epithelial and mesenchymal markers could not be detected in these cells despite the presence of the HNSCC stem cell marker aldehyde dehydrogenase 1 family member A1. Instead, strong expression of B- and T-lymphocytes markers was observed. Flow cytometry analysis revealed a heterogeneous mixture of CD3 + /CD25 + T-lymphocytes and CD19 + B-lymphocytes at a ratio of 4:1 at passage 5 and transformed lymphocytes at late passages (≥ passage 12) with CD45 + CD19 + CD20 + , of which around 10 to 20% were CD3 + CD25 + CD56 + . Interestingly, the whole population was FOXP3-positive indicative of regulatory B-cells (B

conclusionsIn this study we present a primary cell culture of EBV-infected tumor-infiltrating B-lymphocytes, which could be used to study the role of these cells in tumor biology in future research projects. Moreover, by describing the detailed characteristics of these cells, we aim to caution other researchers in the HNSCC field to test for EBV-infected lymphocyte contaminations in primary cell cultures ahead of further experiments. Especially researchers who are interested in TIL-based adopted immunotherapy should exclude these cells in their primary tumor models, e.g. by MDM2-inhibitor treatment. BI-12-derived xenograft tumors represent a suitable model for in vivo targeting studies.

Indexed as

Epstein-Barr Virus InfectionsHead and Neck NeoplasmsAnimalsCell Culture TechniquesCell ProliferationHerpesvirus 4, HumanHumansLymphocytesMiceSquamous Cell Carcinoma of Head and NeckEpstein-barr virusHead and neck cancerHuman papilloma virusLymphocytePrimary cell culture model

Identifiers

PMID36639629
PMCPMC9840248
OpenAlexW4316036609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.